Petro Matad CEO Mike Buck confirmed that he believes the Exploitation Licence for Block XX in Eastern Mongolia is likely to be awarded in Q2. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,282.00
Bid: 7,280.00
Ask: 7,282.00
Change: 11.00 (0.15%)
Spread: 2.00 (0.03%)
Open: 7,252.00
High: 7,287.00
Low: 7,237.00
Yest. Close: 7,271.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials

Wed, 30th Jul 2014 12:00

* Sanofi to file drug for US and EU approval by year-end

* Nine Phase III ODYSSEY trials meet primary endpoint

* Alirocumab "generally well tolerated" in trials

By Natalie Huet

PARIS, July 30 (Reuters) - A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

The injectable drug, called alirocumab, is from a promising new class of medicines, called PCSK9 inhibitors, also being developed by Amgen Inc and other drugmakers. If approved, these drugs could reap annual sales of $3 billion or more, according to some industry analysts.

The Phase III ODYSSEY trials showed that after 24 weeks, the mean percentage reduction in LDL cholesterol with alirocumab was consistent with results seen in previous trials, the companies said in a statement.

The trials involved patients whose high LDL cholesterol levels are not sufficiently controlled by existing treatments such as statins, who cannot tolerate these or who present a high or very high cardiovascular risk.

"The robust data from these studies in more than 5,000 patients is the basis of our global regulatory submissions, which we expect in the U.S. and EU by year-end," said Sanofi R&D chief Elias Zerhouni.

PCSK9 inhibitors block a protein that prevents the body from eliminating LDL cholesterol from the bloodstream and offer a new way of fighting the build-up of artery-clogging fat that puts patients at risk of heart attacks.

These drugs are mainly aimed at the millions of people who either cannot tolerate statins such as Pfizer Inc's Lipitor or AstraZeneca Plc's Crestor or who cannot get their cholesterol levels under control with statins alone.

In earlier mid-stage studies, when combined with statins, alirocumab and Amgen's own PCSK9 drug cut levels of LDL cholesterol by close to 70 percent, more than statins alone.

The drug was "generally well tolerated" in the trials, with most common adverse events being nasopharyngitis, upper respiratory tract infections and injection site reactions.

Serious adverse events and deaths were "generally balanced" between treatment groups as were musculoskeletal, neurocognitive and liver-related events, the companies added.

An interim safety analysis showed that after 18 months of treatment, patients on alirocumab were less prone to cardiovascular events (cardiac death, myocardial infarction, stroke, and unstable angina requiring hospitalization) compared with those on placebo.

Alirocumab's potential to cut cardiovascular risk is being assessed in an ongoing 18,000-patient long-term outcomes trial. (Editing by Mark Potter)

More News

Ireland on track to vaccinate 80% of population by June

Ireland on track to vaccinate 80% of population by June

14 Apr 21 19:43

Greece orders COVID self-testing for service workers

ATHENS, April 14 (Reuters) - Greece will make self-testing for COVID-19 compulsory for service workers in sectors including shops, restaurants and transport, authorities said on Wednesday, as the government looks to gradually reopen the economy.Gr...

14 Apr 21 18:24

Ireland's first dose vaccination target still on track - minister

DUBLIN, April 14 (Reuters) - Ireland's plan for 80% of adults to receive at least one dose of a COVID-19 vaccine by the end of June remains on track after Pfizer Inc-BioNTech announced additional European deliveries on Wednesday, its health minis...

14 Apr 21 17:23

UPDATE 1-Canada will not restrict AstraZeneca COVID-19 vaccine, says benefits outweigh risk

(Adds quote, details)OTTAWA, April 14 (Reuters) - Canada's health ministry said on Wednesday it would not restrict use of AstraZeneca Plc's COVID-19 vaccine after a review showed the benefits outweighed the very rare risk of blood clots.A separate...

14 Apr 21 16:57

LONDON MARKET CLOSE: FTSE ends higher; Goldman up after record quarter

LONDON MARKET CLOSE: FTSE ends higher; Goldman up after record quarter

14 Apr 21 16:55

UPDATE 1-Finland latest to mix COVID-19 vaccines as AstraZeneca crisis delays rollout

(Adds statements by officials, quote on blood clots)HELSINKI, April 14 (Reuters) - Finland said on Wednesday people aged under 65 who got a first dose of the AstraZeneca COVID-19 shot may get a different vaccine for their second dose, as authoriti...

14 Apr 21 16:21

Canada says it won't restrict use of AstraZeneca COVID-19 vaccine at this time

OTTAWA, April 14 (Reuters) - Canada's health ministry said on Wednesday it would not restrict use of AstraZeneca PLC's COVID-19 vaccine at this time after a review showed the benefits outweighed the very rare risk of blood clots.A separate advisor...

14 Apr 21 16:10

Italy suspends distribution of J&J shots after use paused in U.S.

ROME, April 14 (Reuters) - Italy said on Wednesday it had suspended the use of some 184,000 shots of the Johnson & Johnson COVID-19 vaccine, after the brand delayed its introduction in Europe following a health scare in the United States.The firs...

14 Apr 21 15:50

Italians seen increasingly reluctant to accept AstraZeneca shots

By Crispian BalmerROME, April 14 (Reuters) - The head of healthcare management in Italy's largest region, Lombardy, said on Wednesday there was a growing reluctance amongst residents to accept AstraZeneca's COVID-19 vaccine because of safety fears...

14 Apr 21 15:41

AstraZeneca says respects Denmark's decision to stop using its vaccine

FRANKFURT, April 14 (Reuters) - AstraZeneca said on Wednesday it respected the decision of Danish health regulators to stop using the company's COVID-19 vaccine altogether because of a possible link to cases of a very rare type of blood clot."We r...

14 Apr 21 15:23

Denmark scraps use of AstraZeneca vaccine

(Sharecast News) - Denmark has stopped using AstraZeneca's vaccine in its Covid-19 inoculation programme because of concerns about cases of rare blood clots.

14 Apr 21 15:08

UPDATE 2-South Africa says non-refundable downpayments among onerous vaccine terms

* Country has signed big vaccine deals with J&J, Pfizer* Minister says manufacturers made difficult demands* Paused J&J rollout on Tuesday over U.S. blood clot reports* Minister signals pause may be short-lived (Adds quotes, detail, SAHPRA)By Wendel...

14 Apr 21 14:43

UPDATE 1-EU vaccination drive could slip by over 2 months without J&J - Airfinity

(Adds context on delay; AstraZeneca restrictions)By Douglas BusvineBERLIN, April 14 (Reuters) - The suspension of Johnson & Johnson's coronavirus vaccine could delay efforts to inoculate most people in the European Union by over two months, scient...

14 Apr 21 14:20

UPDATE 1-Elderly show similar antibody response to 1st dose of Astra, Pfizer COVID-19 shots -UK study

(Adds scientists' quotes, details, background)By Kate KellandLONDON, April 14 (Reuters) - The first study to directly compare immune reactions between Pfizer's and AstraZeneca's COVID-19 vaccines found strong and broadly similar antibody responses...

14 Apr 21 13:54

TOP NEWS: Denmark to halt use of AstraZeneca Covid-19 vaccine

TOP NEWS: Denmark to halt use of AstraZeneca Covid-19 vaccine

14 Apr 21 13:40

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.